Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
5
×
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
immunotherapy
5
×
indiana blog main
indiana top stories
life sciences
national
5
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
5
×
wisconsin top stories
abbvie
merck
novartis
bristol-myers squibb
cancer immunotherapy
clinical trials
diagnostics
gene therapy
gilead sciences
glaxosmithkline
medicare
alzheimer's disease
What
bio
5
×
roundup
drug
new
patients
abbvie’s
acquisitions
advantages
ahead
albert
approval
bar
biggest
biofourmis
biogen’s
biopharma
biopharmaceutical
bourla
brings
bucks
cancer
car
celebrate
celgene
ceo
chance
colleagues
companies
company
convo
corner
crispr
day
days
earlier
exome
expect
failures
forward
future
Language
unset
unknown
Current search:
immunotherapy
×
national
×
" wisconsin blog main "
×
" boston blog main "
×
bio
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More